請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56969完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖憶純 | |
| dc.contributor.author | Kuan Yang | en |
| dc.contributor.author | 楊寬 | zh_TW |
| dc.date.accessioned | 2021-06-16T06:32:06Z | - |
| dc.date.available | 2019-08-14 | |
| dc.date.copyright | 2014-08-14 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-06 | |
| dc.identifier.citation | Al-Ghamdi S, Albasri A, Cachat J, Ibrahem S, Muhammad BA, Jackson D, et al. (2011). Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PLoS One. 6(6): e20919.
Al-Ghamdi S, Cachat J, Albasri A, Ahmed M, Jackson D, Zaitoun A, et al. (2013). C-terminal tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer. Pancreas. 42(1): 135-140. Albasri A, Al-Ghamdi S, Fadhil W, Aleskandarany M, Liao YC, Jackson D, et al. (2011). Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene. 30(26): 2997-3002. Albasri A, Seth R, Jackson D, Benhasouna A, Crook S, Nateri AS, et al. (2009). C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer. J Pathol. 218(1): 57-65. Barbieri CE, Tang LJ, Brown KA and Pietenpol JA (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 66(15): 7589-7597. Burnette WN (1981). 'Western blotting': electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 112(2): 195-203. Burridge K, Fath K, Kelly T, Nuckolls G and Turner C (1988). Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 4: 487-525. Calderwood DA, Fujioka Y, de Pereda JM, Garcia-Alvarez B, Nakamoto T, Margolis B, et al. (2003). Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A. 100(5): 2272-2277. Calmels S, Hainaut P and Ohshima H (1997). Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 57(16): 3365-3369. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 8(6): 551-561. Chen NT, Kuwabara Y, Conley C, Liao YC, Hong SY, Chen M, et al. (2013). Phylogenetic analysis, expression patterns, and transcriptional regulation of human CTEN gene. Gene. 520(2): 90-97. Daley GQ (2004). Chronic myeloid leukemia: proving ground for cancer stem cells. Cell. 119(3): 314-316. Deyoung MP and Ellisen LW (2007). p63 and p73 in human cancer: defining the network. Oncogene. 26(36): 5169-5183. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, et al. (2002). p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 8(2): 494-501. Fukunishi N, Katoh I, Tomimori Y, Tsukinoki K, Hata R, Nakao A, et al. (2010). Induction of DeltaNp63 by the newly identified keratinocyte-specific transforming growth factor beta Signaling Pathway with Smad2 and IkappaB Kinase alpha in squamous cell carcinoma. Neoplasia. 12(12): 969-979. Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, et al. (2009). Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res. 69(24): 9263-9270. Goldstein AS, Huang J, Guo C, Garraway IP and Witte ON (2010). Identification of a cell of origin for human prostate cancer. Science. 329(5991): 568-571. Grisanzio C and Signoretti S (2008). p63 in prostate biology and pathology. J Cell Biochem. 103(5): 1354-1368. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, et al. (2009). TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 11(12): 1451-1457. Higashikawa K, Yoneda S, Tobiume K, Taki M, Shigeishi H and Kamata N (2007). Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res. 67(19): 9207-9213. Hung SY, Shih YP, Chen M and Lo SH (2013). Up-Regulated Cten by FGF2 Contributes to FGF2-Mediated Cell Migration. Mol Carcinog. Huo H, Magro PG, Pietsch EC, Patel BB and Scotto KW (2010). Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 70(21): 8726-8735. Hynes RO (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69(1): 11-25. Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, et al. (2005). Perp is a p63-regulated gene essential for epithelial integrity. Cell. 120(6): 843-856. Jenuwein T and Allis CD (2001). Translating the histone code. Science. 293(5532): 1074-1080. Jing P, Zou J, Zhang J and Jiang X (2013). DeltaNp63 promotes UMUC3 cell invasiveness and migration through claudin1 in vitro. Mol Med Rep. 7(3): 1026-1030. Jockusch BM, Bubeck P, Giehl K, Kroemker M, Moschner J, Rothkegel M, et al. (1995). The molecular architecture of focal adhesions. Annu Rev Cell Dev Biol. 11: 379-416. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, et al. (2007). A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol. 9(8): 961-969. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, et al. (2011). DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell. 8(2): 164-176. Kommagani R, Leonard MK, Lewis S, Romano RA, Sinha S and Kadakia MP (2009). Regulation of VDR by deltaNp63alpha is associated with inhibition of cell invasion. J Cell Sci. 122(Pt 16): 2828-2835. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 119(6): 861-872. Lechler T and Fuchs E (2005). Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature. 437(7056): 275-280. Lefkimmiatis K, Caratozzolo MF, Merlo P, D'Erchia AM, Navarro B, Levrero M, et al. (2009). p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Cancer Res. 69(22): 8563-8571. Leong CO, Vidnovic N, DeYoung MP, Sgroi D and Ellisen LW (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 117(5): 1370-1380. Li N, Li H, Cherukuri P, Farzan S, Harmes DC and DiRenzo J (2006). TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53. Oncogene. 25(16): 2349-2359. Li Y, Mizokami A, Izumi K, Narimoto K, Shima T, Zhang J, et al. (2010). CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate. 70(1): 48-60. Liao YC, Chen NT, Shih YP, Dong Y and Lo SH (2009). Up-regulation of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer through beta-catenin. Cancer Res. 69(11): 4563-4566. Liao YC, Si L, deVere White RW and Lo SH (2007). The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 176(1): 43-49. Lim do Y and Park JH (2009). Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol. 296(5): G1060-1068. Liu H and Naismith JH (2008). An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol. 8: 91. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25(4): 402-408. Lo SH (2004). Tensin. The International Journal of Biochemistry & Cell Biology. 36(1): 31-34. Lo SH and Lo TB (2002). Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res. 62(15): 4217-4221. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, et al. (2009). Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res. 37(18): 6092-6104. Martuszewska D, Ljungberg B, Johansson M, Landberg G, Oslakovic C, Dahlback B, et al. (2009). Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS One. 4(2): e4350. Mattiske S, Ho K, Noll JE, Neilsen PM, Callen DF and Suetani RJ (2013). TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth. Oncotarget. 4(11): 1894-1903. McDade SS, Patel D and McCance DJ (2011). p63 maintains keratinocyte proliferative capacity through regulation of Skp2-p130 levels. J Cell Sci. 124(Pt 10): 1635-1643. Melino G (2011). p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 18(9): 1487-1499. Natan E and Joerger AC (2012). Structure and kinetic stability of the p63 tetramerization domain. J Mol Biol. 415(3): 503-513. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, et al. (2000). Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res. 60(5): 1348-1352. Oku N, Sasabe E, Ueta E, Yamamoto T and Osaki T (2006). Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 66(10): 5251-5257. Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, et al. (2013). p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLoS One. 8(5): e62547. Parks D, Bolinger R and Mann K (1997). Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. Nucleic Acids Res. 25(6): 1289-1295. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F and Schmitt FC (2003). Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 443(2): 122-132. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP and Ellisen LW (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 9(1): 45-56. Sailer V, Stephan C, Wernert N, Perner S, Jung K, Dietel M, et al. (2013). Comparison of p40 (DeltaNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells? Histopathology. 63(1): 50-56. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, et al. (2008). Prognostic relevance of Tensin4 expression in human gastric cancer. Ann Surg Oncol. 15(9): 2606-2613. Sasaki H, Yukiue H, Kobayashi Y, Fukai I and Fujii Y (2003). Cten mRNA expression is correlated with tumor progression in thymoma. Tumour Biol. 24(5): 271-274. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. (2003). Tight junctions and human diseases. Med Electron Microsc. 36(3): 147-156. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. (2000). p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 157(6): 1769-1775. Sjoestroem C, Khosravi S, Zhang G, Martinka M and Li G (2013). C-terminal tensin-like protein is a novel prognostic marker for primary melanoma patients. PLoS One. 8(11): e80492. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, et al. (2008). Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36(11): 3639-3654. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. (2010). TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 467(7318): 986-990. Thepot A, Hautefeuille A, Cros MP, Abedi-Ardekani B, Petre A, Damour O, et al. (2010). Intraepithelial p63-dependent expression of distinct components of cell adhesion complexes in normal esophageal mucosa and squamous cell carcinoma. Int J Cancer. 127(9): 2051-2062. Thiery JP and Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7(2): 131-142. Tichy V, Navratilova L, Adamik M, Fojta M and Brazdova M (2013). Redox state of p63 and p73 core domains regulates sequence-specific DNA binding. Biochem Biophys Res Commun. 433(4): 445-449. Tokar EJ and Webber MM (2005). Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 22(3): 275-284. Towbin H, Staehelin T and Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 76(9): 4350-4354. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. (2012). Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 109(38): 15312-15317. Urist MJ, Di Como CJ, Lu M-L, Charytonowicz E, Verbel D, Crum CP, et al. (2002). Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. The American Journal of Pathology. 161(4): 1199-1206. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, et al. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 461(7263): 495-500. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, et al. (2002). p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer. 9(3): 216-219. Westfall MD, Mays DJ, Sniezek JC and Pietenpol JA (2003). The Np63 Phosphoprotein Binds the p21 and 14-3-3 Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations. Molecular and Cellular Biology. 23(7): 2264-2276. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, et al. (2011). Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 7(5): 285-295. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 398(6729): 714-718. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, et al. (2006). Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell. 24(4): 593-602. Yilmaz M, Christofori G and Lehembre F (2007). Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med. 13(12): 535-541. Ying H, Chang DL, Zheng H, McKeon F and Xiao ZX (2005). DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol. 25(14): 6154-6164. Zhang Y, Yan W and Chen X (2014). P63 regulates tubular formation via epithelial-to-mesenchymal transition. Oncogene. 33(12): 1548-1557. 莊榮輝 (2010) 酵素純化與分析實驗。SDS 膠體電泳及蛋白質轉印法，莊榮輝主編，國立台灣大學生物技術研究中心，p. 173-175 及 p. 183 張佳鈞 (2013) 表皮生長因子促進 CTEN 基因表現之機制探討，張佳鈞主編，國立台灣大學生命科學院生化科技學系，p. 17 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56969 | - |
| dc.description.abstract | p63 轉錄因子屬於 p53 蛋白質家族的一員,包含六個主要的異構體,在上皮組織 的發育與平衡中扮演重要的角色。p63 的其中一種異構物 ΔNp63α 和 Cten 在前列 腺基底細胞 (basal cells) 中皆大量表現,並且在前列腺癌中表現量大幅降低,其他 研究顯示,knockdown ΔNp63α 或是 Cten 時皆會造成細胞失去貼附能力。而我們 發現 knockdown ΔNp63α 會使得 CTEN 的 mRNA 表現量降低,這樣的現象促使我 們欲研究 ΔNp63α 對於 CTEN 啟動子是否具有 trans-activation 的能力,且細胞生理 是否因此受到影響。因此我們假設 ΔNp63α 能夠 trans-activate CTEN 啟動子,並影 響細胞的貼附與遷移能力。本論文的研究發現,在人類正常前列腺細胞株 RWPE- 1 中, knockdown ΔNp63α 會造成 Cten 的 mRNA 與蛋白質表現量下降,並且證明 了 ΔNp63α 會直接結合在 CTEN 啟動子上,且可能結合於 CTEN 啟動子上的 p53/p63 預測結合序列,而活化 CTEN 的基因表現。此外,knockdown ΔNp63α 會 使得 RWPE-1 細胞株的貼附與移動能力下降,並且在過量表現 Cten 之後貼附與移 動能力回升。除了 in vitro 的實驗,我們也分析了線上資料庫 Oncomine 與 Gene Expression Omnibus (GEO) 所開放下載的前列腺癌症病患之 microarray 資料,我們 發現 TP63 與 CTEN 除了在前列腺癌症中的表現量會下降之外,轉移型癌症的 TP63 與 CTEN 表現量會比原位癌症更進一步地降低,另外,免疫染色的結果顯示, 人類前列腺中的 Cten 與 ΔNp63 之蛋白質表現量與表現位置具有相關性。本論文 證明 ΔNp63α 會結合在 CTEN 的啟動子以調控其基因表現,並透過 Cten 調控細胞 的貼附與移動能力,且可能參與前列腺癌細胞的轉移過程。 | zh_TW |
| dc.description.abstract | p63, a transcription factor of p53 family which contains six major isoforms, is a linchpin of epithelial development and homeostasis. ΔNp63α and Cten are both highly expressed in normal prostate basal cells and down-regulated in prostate cancer. previous evidence has indicated that knockdown of either Cten or ΔNp63α would cause decrease in cell adhesion. Moreover, we discovered that ΔNp63α depletion by siRNA results in reduced CTEN mRNA level. It prompted us to investigate whether CTEN promoter is trans-activated by ΔNp63α and the resulting cell morphological changes. Therefore, we hypothesized that ΔNp63α would trans-activate CTEN expression and subsequently lead to affects cell adhesion and mobility, which could possibly have connection with cancer metastasis. In our study, siRNA-mediated knockdown of ΔNp63α caused decrease of Cten expression in normal prostate cell line RWPE-1. Moreover, we showed that ΔNp63α physically binds to CTEN promoter and the putative p53/p63 consensus binding sites are critical for ΔNp63α binding and activation. In addition, we demonstrated that knockdown of p63 results in decrease of cellular adhesion and migration, which could be rescued by over-expression of Cten. Consistent with our in vitro findings, we confirmed a positive correlation between TP63 and CTEN expression by analyzing the microarray data set from online database Oncomine and Gene Expression Omnibus (GEO). Based on these downloaded data set, we also discovered that the expressions of TP63 and CTEN in metastatic cancers are both lower than those in primary cancers. Additionally, immunohistochemical staining analysis showed a correlation between Cten and ΔNp63 expression and localization in human prostate. Altogether, our findings revealed that ΔNp63α regulates the expression of CTEN by trans-activating its promoter, and CTEN up-regulation results in increased capacity of cell adhesion and migration ability. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T06:32:06Z (GMT). No. of bitstreams: 1 ntu-103-R01b22028-1.pdf: 4819547 bytes, checksum: 7eb8ca0d669ff4eb8d93726c4549c9b2 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 縮寫表: iv
中文摘要: vi 英文摘要: vii 1 本論文之研究基礎: 1 1.1 p63 的結構與功能: 1 1.2 ΔNp63α對細胞移動與貼附的影響: 2 1.3 Cten 的結構與功能: 4 1.4 Cten 在調控細胞貼附與遷移中所扮演的角色: 5 1.5 Cten可能為 ΔNp63α 調控的下游基因: 5 1.6 本論文之研究目的與重要性: 7 2 材料與方法: 8 2.1 實驗材料: 8 2.2 細胞相關實驗方法: 10 2.3 Cell adhesion assay: 12 2.4 Cell migration assay: 13 2.5 DNA 分析與質體建構: 14 2.6 RNA 分析: 17 2.7 蛋白質分析: 18 2.8 Dual luciferase assay: 19 2.9 染色質免疫沈澱 (chromatin Immuno-precipitation assay, ChIP): 19 2.10 生物資訊學分析: 22 2.11 免疫染色 (Immunohistochemistry, IHC): 23 3 研究結果: 25 3.1 TP63 與 CTEN 於前列腺細胞株中的表現: 25 3.2 ΔNp63α 影響 Cten mRNA 與蛋白質的表現量: 25 3.3 ΔNp63α 活化 CTEN 啟動子的轉錄活性: 26 3.4 尋找 ΔNp63α 於 CTEN 啟動子上的結合序列: 27 3.5 p53 對 CTEN 啟動子活性的影響: 27 3.6 ΔNp63α 結合於 CTEN 啟動子之序列: 28 3.7 ΔNp63α經由活化CTEN 基因以維持細胞貼附能力: 28 3.8 ΔNp63α 經由活化 CTEN 基因促使細胞移動能力增加: 29 3.9 生物資訊學分析: 29 3.10 人類前列腺中的 ΔNp63 與 Cten 之蛋白質含量具有相關性: 30 4 討論與未來的研究方向: 31 5 參考文獻: 38 6 圖與表: 44 | |
| dc.language.iso | zh-TW | |
| dc.subject | 細胞貼附 | zh_TW |
| dc.subject | 前列腺癌 | zh_TW |
| dc.subject | 細胞移動 | zh_TW |
| dc.subject | cell adhesion | en |
| dc.subject | prostate cancer | en |
| dc.subject | p63 | en |
| dc.subject | Cten | en |
| dc.subject | cell migration | en |
| dc.title | 前列腺細胞中 ΔNp63α 調控 CTEN 基因進而參與細胞貼附與遷移機制 | zh_TW |
| dc.title | CTEN is a target gene of ΔNp63α involved in prostate cell adhesion and migration | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 冀宏源,張麗冠,王愛玉,謝淑貞 | |
| dc.subject.keyword | 細胞貼附,前列腺癌,細胞移動, | zh_TW |
| dc.subject.keyword | cell adhesion,cell migration,Cten,p63,prostate cancer, | en |
| dc.relation.page | 67 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-06 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 4.71 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。